Ingalls & Snyder LLC purchased a new stake in shares of Neurotrope Inc (NASDAQ:NTRP) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 33,700 shares of the company’s stock, valued at approximately $326,000.

Separately, Cannell Peter B & Co. Inc. raised its position in Neurotrope by 14.2% during the first quarter. Cannell Peter B & Co. Inc. now owns 270,793 shares of the company’s stock valued at $2,199,000 after purchasing an additional 33,600 shares in the last quarter. 16.83% of the stock is owned by hedge funds and other institutional investors.

NTRP has been the topic of a number of research reports. Zacks Investment Research downgraded Neurotrope from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Maxim Group started coverage on Neurotrope in a research report on Wednesday, May 16th. They set a “buy” rating and a $16.00 price target on the stock. Finally, ValuEngine upgraded Neurotrope from a “hold” rating to a “buy” rating in a report on Tuesday, May 22nd.

Shares of NASDAQ:NTRP opened at $9.18 on Friday. Neurotrope Inc has a 1 year low of $3.97 and a 1 year high of $11.93.

Neurotrope Profile

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Read More: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding NTRP? Visit to get the latest 13F filings and insider trades for Neurotrope Inc (NASDAQ:NTRP).

Institutional Ownership by Quarter for Neurotrope (NASDAQ:NTRP)

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with's FREE daily email newsletter.